HC Wainwright Boosts Kura Oncology (NASDAQ:KURA) Price Target to $40.00

Kura Oncology (NASDAQ:KURA) had its target price lifted by HC Wainwright from $37.00 to $40.00 in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms also recently commented on KURA. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Bank of America cut their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Scotiabank lowered their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Stock Down 2.5 %

NASDAQ KURA opened at $8.82 on Thursday. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $8.79 and a 200-day moving average of $15.11.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the firm earned ($0.50) earnings per share. As a group, equities research analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,255 shares of company stock valued at $100,739 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently made changes to their positions in KURA. Suvretta Capital Management LLC lifted its stake in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after acquiring an additional 583,155 shares during the period. Alethea Capital Management LLC lifted its position in shares of Kura Oncology by 108.2% in the 3rd quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock worth $10,816,000 after purchasing an additional 287,636 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Kura Oncology in the 3rd quarter valued at $3,695,000. Barclays PLC increased its position in shares of Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after buying an additional 84,563 shares during the period. Finally, Jennison Associates LLC bought a new position in Kura Oncology during the fourth quarter worth $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.